| abstract |
The invention provides the use of a compound of the formula (I)n n and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R₁ is hydrogen, R₂ is C₁₋₄ alkyl or C₁₋₄ alkoxy, the 2-imidazolin-2-ylamino group is in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R₃, R₄ and R₅ are each located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and are independently selected from Cl, Br, hydrogen and C₁₋₃ alkyl, for the manufacture of a medicament for reducing or maintaining intraocular pressure in a mammalian eye, for example an eye affected by glaucoma. nAlso provided is the use of a compound of the formula (II)n n and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R₁ and R₂ are independently selected from hydrogen, C₁₋₄ alkyl and C₁₋₄ alkoxy; the 2-imidazolin-2-ylamino group is in any of the 6-, 7- or 8- positions of the quinoxaline nucleus, R₃ is hydrogen or C₁₋₃ alkyl, and R₄ and R₅ each are located in one of the remaining 6-, 7- or 8-positions of the quinoxaline nucleus and are selected from Cl, Br, H and C₁₋₃ alkyl radicals, for the manufacture of a medicament for reducing or maintaining the intraocular pressure in a mammalian eye, for example an eye affected by glaucoma. n The invention also provides topical ophthalmic compositions comprising a compound of the formula (I) or (II) and an ophthalmically acceptable carrier. |